BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s): BVAXF

Healthcare Biotechnology

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.

CSE:BIOV - Post by User

BioVaxys Technology Corp.

<< Previous

Bullboard Posts

Next >>

Post by rich47on Dec 07, 2024 2:52pm

97 Views

Post# 36351164

Easy peasy go to top of page click insiders on this page

You will see CEO Passin (James). Click on it. You will see CEO Passin holds 19,177,133 shares held. You will also see the $300,000 (6,000,000) shares purchase during the last private placement he participated in (2024-9-11).

You can also click top of page the Ownership button and see Kovan (Kenneth) 6,949,542 held shares. Of course their is always Canadian Insider or SEDI direct.

<< Previous

Bullboard Posts

Next >>

BoC’s Double Rate Cut: Is it a benefit for Canadians